SCHEMBL206649

SCHEMBL206649

CN(C)C1(Cc2ccc(Cl)cc2)CCC(NC(=O)CCC(=O)Nc2ccc(CP(=O)(O)O)cc2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 6/20 0.44
DGAT2 Q96PD7 1/20 0.44
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.39
POLB P06746 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
TP53 P04637 1/20 0.38
GAA P10253 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ALDH1A1 P00352 2/20 0.37
TMEM97 Q5BJF2 1/20 0.37
SIGMAR1 Q99720 1/20 0.37
P2RX7 Q99572 1/20 0.37
F10 P00742 1/20 0.37
CACNA1G O43497 1/20 0.36
NPC1 O15118 1/20 0.36
EPHX1 P07099 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL205569 0.90 ENPP2 (0.46) ENPP2DGAT2HPGDMEN1KMT2A
SCHEMBL4074093 0.88 MEN1 (0.38) ENPP2DGAT2LMNAHPGDPOLB
SCHEMBL5160624 0.87 LMNA (0.43) LMNAHPGDPOLBMEN1KMT2A
SCHEMBL207874 0.86 KMT2A (0.55) LMNAHPGDPOLBMEN1KMT2A
SCHEMBL206628 0.85 SSTR4 (0.42) ENPP2DGAT2HPGDMEN1KMT2A
SCHEMBL207100 0.83 NPSR1 (0.43) LMNAHPGDPOLBMEN1KMT2A
SCHEMBL206987 0.83 POLB (0.56) LMNAHPGDPOLBMEN1KMT2A
SCHEMBL206932 0.81 LMNA (0.46) LMNAHPGDPOLBMEN1KMT2A
Butane SCHEMBL4074088 0.81 MEN1 (0.38) LMNAHPGDPOLBMEN1KMT2A
SCHEMBL4081068 0.80 THRB (0.39) ENPP2HPGDMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US claimed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP claimed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US claimed
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US disclosed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds PKD1, DDC, DPYD ENPP2 3277/4885DGAT2 1549/4885LMNA 1995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.